Cargando…
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
BACKGROUND: An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estimated 30–80% of advanced solid tumors harbor actionable gen...
Autores principales: | Kringelbach, Tina, Højgaard, Martin, Rohrberg, Kristoffer, Spanggaard, Iben, Laursen, Britt Elmedal, Ladekarl, Morten, Haslund, Charlotte Aaquist, Harsløf, Laurine, Belcaid, Laila, Gehl, Julie, Søndergaard, Lise, Eefsen, Rikke Løvendahl, Hansen, Karin Holmskov, Kodahl, Annette Raskov, Jensen, Lars Henrik, Holt, Marianne Ingerslev, Oellegaard, Trine Heide, Yde, Christina Westmose, Ahlborn, Lise Barlebo, Lassen, Ulrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948467/ https://www.ncbi.nlm.nih.gov/pubmed/36814246 http://dx.doi.org/10.1186/s12885-023-10632-9 |
Ejemplares similares
-
Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients
por: Viller Tuxen, Ida, et al.
Publicado: (2019) -
Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment
por: Frank, Malene Støchkel, et al.
Publicado: (2021) -
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors
por: Ahlborn, Lise Barlebo, et al.
Publicado: (2018) -
ProTarget: automatic prediction of protein structure novelty
por: Sasson, Ori, et al.
Publicado: (2005) -
Application of cell-free DNA for genomic tumor profiling: a feasibility study
por: Ahlborn, Lise B., et al.
Publicado: (2019)